

Supplemental material

Supplement to:

The effect of adding bezafibrate to standard lipid-lowering therapy on fasting and post-fat load lipids in patients with Familial Dysbetalipoproteinemia. A randomized, placebo-controlled, crossover trial.

C. Koopal, MD, A. David Marais, MD, Jan Westerink, MD PhD, Y. van der Graaf, MD PhD, F.L.J. Visseren, MD PhD

To whom correspondence should be addressed:

Email: F.L.J.Visseren@umcutrecht.nl

Supplemental Table S1: Reported side effects.

Pt	Side-effect	Study drug	Background lipid lowering therapy
1	Gastro-intestinal complaints	Bezafibrate	Lifestyle + simvastatin 40 mg + ezetimibe 10 mg
2	Increase in former complaints of fatigue and flatulence	Placebo	Lifestyle + atorvastatin 10 mg
3	Myalgia + CK 1718 U/L	Bezafibrate	Lifestyle
4	Myalgia	Placebo + Bezafibrate	Lifestyle + atorvastatin 20 mg
5	Myalgia	Placebo + Bezafibrate	Lifestyle + simvastatin 40 mg
6	Myalgia	Placebo	Lifestyle
7	Gastro-intestinal complaints	Placebo	Lifestyle + atorvastatin 10 mg + ezetimibe 10 mg